Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia

American Journal of Hematology

Volumn 51, Issue 2, 1996, Pages 117-121

  Kritz, Alan D ^a,b   Raptis, George ^a   Menendez Botet, Celia ^a   Maslak, Peter ^a   Jakubowski, Ann ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

5 azacytidine; Carboplatin; Leukemia

Indexed keywords

AZACITIDINE; CARBOPLATIN;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; STOMATITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CARBOPLATIN; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE;

EID: 0030064474     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199602)51:2<117::AID-AJH4>3.0.CO;2-0     Document Type: Article

References (17)

1. Reed E, DeVita V, Helman S, Rosenberg S (eds). "Platinum Analogs in Cancer Principles and Practice of Oncology," Ed 4. Philadelphia, PA: Lippincott, 1993, pp 390-400.
2. Lee E, Egorin M, Van Echo D, Cohen A, Tait N, Schiffer C: Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. JNCI 2:131-135, 1988
3. Meyers F, Welborn J, Lewis J, Flynn N: Infusional carboplatin treatment of relapsed and refractory acute leukemia: Evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 7:173-178, 1989.
4. Martinez J, Martin G, Sanz A, Sempere A, Jarque I, de la Rubia J, Sanz M: A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol 1:39-43, 1991.
5. Vogler WR, Harrington DP, Winton EF, Lazarus HM, Bennett JM, Cassileth PA, Oken MM: Phase II clinical trial of carboplatin in relapsed and refractory leukemia. Leukemia 6:1072-1075, 1992.
6. Pinto A, Zagonel V: 5-aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute leukemias and myelodysplastic syndromes: Past, present and future trends. Leukemia 7:51-60, 1993
7. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R: The antileukemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukemia. Br J Cancer 64:144-148, 1991.
8. Willemze R, Archimbaud E, Muus P: Preliminary Results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. Leukemia 7:49-50, 1993.
9. Petti MC, Mandelli F, Zagonel V, De Gregoris C, Merola MC, Latagliata R, Gattei V, Fazi P, Monfardini S, Pinto A: Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary Results. Leukemia 7:36-41, 1993.
10. Cheson B, Cassileth P, Head D, Schiffer C, Bennett J, Bloomfield,: Report of the National Cancer Institute-sponsored Workshop on Definitions of Diagnosis and Response in Acute Myeloid Leukemia. J Clin Oncol 9:813-819, 1990.
11. Menendez-Botet C, Schwartz M: Clinical chemistry trace metals. Anal Chem 63:194-199, 1991.
12. Reed E, Ormond P, Bohr V, Budd J, Bostick-Bruton F: Expression of the human DNA repair gene ERCC-1 related to cisplatinum drug resistance in human ovarian cancer cells. Proc Am Assoc Cancer Res 30:488, 1989 (abstract).
13. Nyce J: Drug-induced DNA hypermethylation and drug resistance. Cancer Res 49.5829-5836, 1989.
14. Dutcher JP, Eudey L, Wiernik PH, Paietta E, Bennett J, Arlin Z, Kellermeyer R, Rowe J, O'Connell M, Oken M, Cassileth PA: Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Leukemia 6:770-775, 1992.
15. Archimbaud E, Anglaret B, Thomas X, De Vaux Y, French M, Sebban C, Troncy J, Fiere D: Continuous-infusion daunorubicin and carboplatin for high-risk acute myelogenous leukemia in the elderly. Leukemia 6:776-779, 1992
16. Lee E, Reck K, Carter C, Hodges S, Schiffer C: A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia. Leukemia 7:1500-1503, 1993.
17. 1210 cells in vitro associated with almost complete loss of deoxycytidine kinase activity. Neoplasm 34.713-720, 1987.